What is Johnson & Johnson's (JNJ) Economic Moat, and is it Widening or Narrowing?
Johnson & Johnson (NYSE:JNJ) closed at $264.74 on September 30, almost 43% higher than a year ago and within a few percent of its record.
Johnson & Johnson (JNJ)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 13,307,056 | $3,379,593,434 | +44% | 1.01% |
| 2. | 3,673,700 | $933,009,589 | -2% | 0.11% | |
| 3. | 3,214,000 | $816,259,580 | +28% | 0.09% | |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,989,537 | $759,252,713 | +26% | 0.6% |
| 5. | AQR Capital Management Cliff Asness | 2,907,803 | $738,494,690 | -18% | 0.26% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $206.15 | 1,250 | $257,687.50 | 1,849 | 2025-11-26 | Filing | |
| $145.53 | 100 | $14,553.00 | 250 | 2024-04-30 | Filing | |
| $147.22 | 1,000 | $147,220.00 | 1,000 | 2024-12-12 | Filing | |
| $127.69 | 500 | $63,843.00 | 16,030 | 2020-03-13 | Filing | |
| $141.28 | 5,000 | $706,399.00 | 5,000 | 2019-12-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $274.74 | 22,527 | $6,189,067.98 | 25,447 | 2026-09-02 | Filing | |
| $274.74 | 11,070 | $3,041,371.80 | 25,447 | 2026-09-02 | Filing | |
| $263.36 | 15,000 | $3,950,400.00 | 194,451 | 2026-08-17 | Filing | |
| $261.00 | 102,315 | $26,704,215.00 | 275,967 | 2026-08-13 | Filing | |
| $262.00 | 20,976 | $5,495,712.00 | 378,282 | 2026-08-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 258,168 | $69,078,012 | 3.65% | |
| 2. | 38,550 | $10,205,809 | 0.75% | |
| 3. | 17,686 | $4,682,192 | 0.34% | |
| 4. | 17,058 | $4,515,935 | 0.68% | |
| 5. | 9,885 | $2,616,955 | 0.57% |
News See All
Muse AI Agent Stock Portfolio: 2 Non-AI Stock Picks You Should Not Miss
Note: The stock trades in this article come from Rallies Arena, an account on X (@ralliesarena) that runs the Rallies AI Stock Market Arena, an experiment where AI models manage stock portfolios and try...
3 Best ETFs with 12%+ Upside, According to AI Analyst
Exchange-traded funds (ETFs) remain a key way to capture growth opportunities in the market. Investors seeking exposure to industries such as tech,...
Can J&J’s Latest Trial Win Strengthen its Neuroscience Business?
Johnson & Johnson's (NYSE:JNJ) $14.6 billion acquisition of Intra-Cellular Therapies has gained another potential growth avenue after Caplyta met the main goal of a late-stage study in bipolar mania.
Is Johnson & Johnson (JNJ) Building a Stronger Post-Stelara Growth Story?
On September 25, Johnson & Johnson (NYSE:JNJ) announced top-line findings from its Phase 4 STAR study evaluating Tremfya (guselkumab) in biologic-naïve adults with active psoriatic arthritis (PsA) and...
10 Best Healthcare Stocks to Buy According to Hedge Funds
Healthcare has rarely been short of investment opportunities, but deciding where to look has become more complicated.
Can J&J’s Partnership Drive More Upside for Nanobiotix?
Guggenheim has assumed coverage of Nanobiotix S.A.
Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?
Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) offer investors two very different versions of pharmaceutical growth.
3 ETFs That Could Deliver 11%+ Returns, According to the AI Analyst
TipRanks’ ETF AI Analyst has an Outperform rating on the Schwab U.S. Dividend Equity ETF ($SCHD), Health Care Select Sector SPDR Fund ($XLV), and V...
Apollo’s Johnson & Johnson Deal Could Open a New Healthcare Growth Avenue
It was reported on September 11 that Apollo Global Management, Inc.
Hedge Fund Resource Center